Alto Neuroscience, Inc. Proceeds from Long-Term Debt Issued
Alto Neuroscience, Inc. (ANRO) reported Proceeds from Long-Term Debt Issued of $19.69 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2025-05-14
- Alto Neuroscience, Inc. proceeds from issuance of long-term debt for the quarter ending 2025-03-31 was $19.69M.
- Alto Neuroscience, Inc. proceeds from issuance of long-term debt for the quarter ending 2024-03-31 was $0.00.
| Period end | Proceeds from Issuance of Long-term Debt 3 month |
|---|---|
| 2025-03-31 | $19.69M 10-Q · filed 2025-05-14 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |